We suggest that 213Bi-C595 may have the potential to target micrometastatic pancreatic cancer cells with MUC1 overexpression and represent a new therapeutic modality for the control of pancreatic cancer metastases. Here, MUC1 is linked to familial pancreatic carcinoma.